ArticleJTO clinical and research reports2025

Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.

Sanjana Mullangi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.